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BCC is the most common cancer worldwide and its incidence is still rising, by 3-10% annu-
ally. However, as there are few adequate skin cancer registries, the actual increase might be 
even higher. Although BCCs rarely metastasize and mortality is extremely low, they can cause 
significant morbidity due to locally aggressive behavior. Half of all BCC arise primarily on the 
face and (bald) scalp. Surgical excision, which is the current gold standard of treatment, has 
disadvantages, such as the risk of bleeding, infection, impaired healing and scarring, which 
can be disfiguring and cause patients to experience a significantly decreased quality of life. 
The high incidence of BCC combined with the associated high costs of treatment and the 
attendant workload is causing a significant and mounting impact on the health-care system. 
Consequently, BCC is an important public health problem. For that reason, there is an urgent 
medical and societal need for a patient friendly and cheap (targeted) non-invasive treatment, 
and preferably one that can be performed by patients themselves. To develop such a treat-
ment, a profound understanding of BCC pathogenesis is essential. The research described 
in this thesis aims to profile genetic and epigenetic alterations in both non-aggressive and 
locally advanced BCC in order to enhance our understanding of BCC pathogenesis. This 
will be described in part one. Part two discusses new topical and systemic drugs in the 
treatment of BCCs.
Part one: pathogenesis of BCC
Epigenetics and more in BCC
Epigenetics encompasses heritable changes in gene expression without changes in the DNA 
sequence. These changes can be present at the DNA (DNA methylation), RNA (RNA inter-
ference by non-coding RNAs), and protein (histone modifications, polycomb group proteins, 
and chromatin remodeling) level. The continuous interplay of these epigenetic regulations 
determines the organism’s phenotype, which is referred to as the epigenome.1,2 The studies 
presented in this thesis focus on DNA-methylation, one of the most important and well-stud-
ied epigenetic alterations. DNA methylation consists of adding a methyl group to cytosine 
nucleotides, primarily when they are followed by a guanine, the so-called CpG dinucleotide. 
Aberrant DNA methylation patterns are seen in many cancers (o.a. colon, breast, kidney and 
prostate cancer)1 and other human diseases, such as autoimmune and neurological disor-
ders.3 In BCCs, however, only a few studies have so far looked at DNA methylation. Also, 
these studies focused on predefined tumor suppressor genes and did not provide evidence 
that any observed changes in methylation patterns were relevant for BCC carcinogenesis.4-9 
Additional evidence shows that ultraviolet (UV) radiation A and UVB may alter epigenetic mod-
ifications10 and UV-signature mutations seem to preferentially occur at methylated C-phos-
phate-G (mCpG) dinucleotides.11 As BCCs mainly occur at sun-exposed areas of the skin12, they 
might be expected to show extensive methylation changes compared to non-diseased skin.
In a first exploration of promoter hypermethylation in BCCs, we assessed the promoter CpG 
island methylation status of nine candidate tumor suppressor genes (TSG). CpG islands 
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are regions with a higher frequency of CpG dinucleotides that are mostly found around 
the promoter region of the gene.13 As described in chapter 2.1, nested methylation spe-
cific polymerase chain reaction (MSP) was performed on bisulfite-modified genomic DNA 
of BCCs and healthy skin with primers specific for methylated DNA, respectively unmeth-
ylated DNA. Significantly more DNA methylation in BCCs was found in the gene promot-
ers of SHH, APC and SFRP5, all key regulators of the SHH and WNT signaling pathways, 
and of RASSF1A. RASSF1A is a well-known tumor suppressor of which epigenetic inac-
tivation is previously described in BCCs9, but also in malignant melanoma14 and Merkel 
cell carcinoma.15 Interestingly, healthy sun-exposed (SE) skin samples showed methyl-
ation patterns similar to sun-protected (SP) skin, suggesting that the methylation we ob-
served is more tumor-specific than locus or patient specific, a finding that is in line with 
literature to date.16 It is of interest that methylation patterns in sun-exposed skin did not 
resemble those in BCC. Our findings therefore do not support a contribution of UVB ex-
posure to the observed promoter hypermethylation of SHH, APC, SFRP5 and RASSF1A. 
However, since the epigenetic changes that we found parallel genetic changes driving BCC 
growth, it seems likely that gene silencing by promoter hypermethylation is relevant to BCCs. 
In this study we used nested MSP because it is highly sensitive and can detect 1 methyl-
ated allele in >50,000 unmethylated alleles. This makes it exquisitely suitable for methyla-
tion analysis of archived formalin-fixed paraffin-embedded (FFPE) DNA, as this generally 
yields small amounts of poor quality DNA.17 Since biopsy or excision tissue samples tak-
en during regular care are commonly FFPE and stored in the archives of the pathology 
department, there is wealth of tissue available for research. On the down side, (nested) 
MSP is a ‘yes or no’ approach that does not provide quantitative results. Also, it can only 
be used to screen pre-defined candidate genes. Fortunately, novel techniques such as 
comprehensive probe-based, bisulfite whole- genome sequencing, and enrichment-based 
technologies18-20 allow unbiased genomewide analysis of DNA methylation (the “methy-
lome”). This is a major advantage compared to locus-specific, low-throughput approaches 
that are typically PCR based. However, the latter are still used for validation purposes.19
Chapter 2.2 describes the first analysis of the BCC methylome by genome-wide mCpG DNA 
enrichment sequencing (MethylCap-seq).21 MethylCap-seq is based on capture of meth-
ylated DNA on a genome-wide scale with the methyl-DNA binding domain (MBD) domain 
of the protein MeCP2. As only methylated DNA is subsequently sequenced, the complex-
ity of the analysis is reduced and high sequence coverage can be obtained.22 Methyl-
Cap-seq is a robust, highly reproducible approach, especially for larger sample cohorts.22
 
We identified 32979 methylated regions in 22121 genes, 13 of which were differentially meth-
ylated in sporadic BCCs compared to healthy skin, with a False Discovery Rate (FDR) of <0.1 
(chapter 2.2). As methylation can regulate gene expression levels23, we performed rRNA 
depleted, strand specific, total RNA sequencing (RNA-seq henceforth) and correlated these 
data to the methylome. This correlation provides information on the functional methylome: 
i.e. those methylation events that affect gene expression. Of note, there was little overlap 
184 | Chapter 6
between the top-ranked differentially methylated loci and differentially expressed genes 
(FDR<0.1), even when preselecting for genes that might be differentially expressed in BCC. 
At present, we cannot explain this finding. The full spectrum of functions that DNA-methyla-
tion has remains to be delineated, as is its full impact on RNA expression levels. IFI30 was 
one of the hits that was both differentially methylated and differentially expressed, a finding 
that points to the importance of immune signaling in BCC. IFI30 is known to play a criti-
cal immunoregulatory role in melanoma by mediating antitumor immunity via CD4+ T-cells.24
 
We compared the results of our first analysis in BCC with those obtained from methyl-
Cap-seq and RNA analysis of a facial laBCC (chapter 2.3). We identified considerable 
agreements and differences between the non-aggressive and aggressive BCCs. The most 
striking difference was a dramatic increase in expression of matrix metalloproteinase 13 
(MMP13) in the laBCC, which could explain the more aggressive behavior of this tumor.25
Additional pathway analysis of the RNA-seq data was performed with SPIA soft-
ware26, showing that pathways activated in BCC are all involved in immune signa-
ling: cytokine-cytokine receptor interaction signaling (KEGG hsa04060), chemok-
ine signaling (Chemokine) (KEGG hsa04062) and Toll-like receptor signaling (KEGG 
hsa04620). Pathway enrichment analysis of the differentially methylated genes also re-
vealed cytokine-cytokine receptor interaction as the most significant pathway. The im-
portance of immune signaling in BCCs is further supported by results from our inde-
pendent clinical trial, described in chapter 4.1. Previous work has also found increased 
expression of innate immune genes in squamous cell carcinomas (SCCs) and in BCCs.27
 
Apparently, SHH signaling might not be the sole driver in sporadic BCCs. In fact, BCC 
pathogenesis seems to be rather complex, and this is further confirmed by the whole-exome 
sequencing of BCCs described by Jayaraman et.al.28 Surprisingly, although BCC can be 
considered as the least malignant human cancer, they harbor the largest mutational burden 
compared to any other known human malignancy. The vast majority of mutations (75.7%) 
showed a clear UV signature. However, Jayaraman et.al. could not identify any novel genes 
as drivers in BCC. The authors hypothesized that the resulting high level of mutated proteins 
might increase the hosts’ immune response, resulting in a less aggressive phenotype.28 It is 
of interest that the incidence of nonmelanoma skin cancer (NMSC) in immunosuppressed 
patients, such as organ transplant recipients (OTR), is up to 250-fold higher than in the gen-
eral population. For common cancers like gastrointestinal, lung, breast, bladder, prostate, 
and gynecological, this risk is only two to five-fold higher.29,30 In OTR, SCCs occur 4-10 times 
more often than BCCs and tend to behave in a more aggressive manner with increased met-
astatic potential, and higher recurrence rates compared to SCC in non-immunocompromised 
people.30,31 This increased risk of SCCs and also BCCs may be due to the higher rates of 
human papillomavirus (HPV) infection in immunosuppressed populations, however the most 
convincing evidence is available for the link between HPV and SCC. An etiologic association 
between HPV and BCC remains to be elucidated.32 In addition to viral oncogenic infections, 
decreased immune-surveillance and the direct effect of the immunosuppressive medications 
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used by OTR causes them to be more vulnerable to NMSC development.32 The influence of 
an immune response in BCC development was previously reported and shows that trans-
plantation of human BCC biopsies is only successful in mice deficient of T, B and natural 
killer (NK) cells.33 However, BCC nest are frequently, but not always, surrounded by an infil-
trate consisting of T cells and only very few B lymphocytes and NK cells that do generally not 
invade the tumor nests.34 Although complete tumor eradication is rare30, higher number of T 
cells is seen in actively regressing BCCs.34 Generally, BCCs express no or low levels of MHC 
class I (MHC-I) molecules and as a consequence there is an absence of infiltrating CD8+ 
effector T cells. Following treatment with topical imiquimod, a Toll-like receptor-7 antagonist, 
significantly higher expression levels of MHC-I accompanied by an increase of peritumoral 
CD8+ T cells were seen.30 This pro-inflammatory Th1 initiated anti-tumor immune response 
has also been implicated in the well-established spontaneous regression of BCC after a biop-
sy.35 Also, A Th2 anti-inflammatory response has been described in BCCs, which suggests a 
dynamic state in where pro- and anti-inflammatory immune response coexist and compete.36 
The exact mechanisms underlying an effective tumor specific immune response is unclear 
as there are still many missing links. In our study described in chapter 4.1, an extensive infil-
trate was seen in the BCCs treated with topical diclofenac, in the majority of the cases even 
resulting in complete histological tumor regression. The nature of this immuneresponse will 
be analyzed in a future study in an attempt to unravel the role of the BCC immuneresponse.
DNA methylation in BCC and the future
As epigenetic alterations are potentially reversible, drugs have been developed to inhibit en-
zymes that catalyze epigenetic modifications. In the case of DNA methylation, these are the 
DNA methyltransferases (DNMTs), consisting of 3 main subtypes. DNMT1 maintains existing 
methylation during DNA replication, while DNMT3A and DNMT3B are required for de novo 
methylation. To date, the FDA has approved two demethylating drugs for the treatment of 
higher-risk myelodysplastic syndrome: 5-azacytidine (5-aza-CR; manufactured by Celgene 
as Vidaza) and 5-aza-2′-deoxycytidine (5-aza-CdR; manufactured by Eisai as Dacogen). 
However, these drugs have substantial side effects, which makes them less useful for BCC 
treatment, as the advantage of being a non-invasive treatment will not outweigh these side ef-
fects.37 The systemic side effects could be avoided by using the 5-aza’s topically. Unfortunate-
ly, they are both pharmalogically unstable agents, which impedes their topical formulation.
 
Whereas DNA methylation changes in cancer constitute a potential target for treat-
ment, they could also be used to develop biomarkers for more accurate detection of 
cancer, a better insight in tumor prognosis, and even to predict treatment response.2 In 
contrast to genetic biomarkers that detect the numerous different point mutations oc-
curring throughout the length of the gene, DNA hypermethylation consistently affects a 
small promoter region, facilitating analysis. Also, DNA methylation alterations occur in 
higher percentages of tumors than genetic variations, resulting in a higher sensitivity.37 
The utility of biomarkers for BCC treatment can be debated, as these tumors are gener-
ally characterized by indolent growth, an excellent prognosis and easy accessibility 
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for assessment and treatment. However, given the large number of patients that will de-
velop at least one or more subsequent BCC after the first BCC, a prognostic biomarker 
that could predict the individual risk of (recurrent) BCC could be extremely useful. It 
would enable classification of patients as having a low, an intermediate or a high risk of 
developing BCC. Using this information, follow-up schemes could be tailored to the pa-
tient’s individual risk, thereby making care for BCC more efficient and cost-effective.
Beyond DNA methylation 
In our work, we focused on DNA (cytosine) methylation, because it is the best-defined epige-
netic change in malignancy. Hydroxymethylation of cytosine (5-hmC) is a more recently de-
scribed modification, that affects the flexibility and stability of DNA differently from methylation. 
The 5-hmC level is strongly reduced in tumors of the brain, kidney, lungs, skin and liver, from 
which it was suggested that 5-hmC loss could serve as biomarker for the detection of can-
cers. However, the exact role of 5-hmC in the development of cancer remains unknown.38,39 
Additional epigenetic modifications that have been found to be involved in human cancers 
include histone modifications, chromatin remodeling and the activity of non-coding RNAs 
(ncRNAs).3,40 These different processes work together to establish and maintain the glob-
al and local condensed or decondensed chromatin states that eventually determine gene 
expression.2 DNA is tightly compacted around histones to the nucleosome which is the ba-
sic unit of the chromatin.40 These histones can be modified post-transcriptionally by (hyper)
acetylation, methylation, phosphorylation and ubiquination. Those different processes af-
fect, among others, transcriptional regulation, DNA repair, DNA replication, alternative splic-
ing, and chromosome condensation.3 Hyperacetylation of the lysines in histone tails is the 
best described modification and is facilitated by Histone Acetyltransferases (HATs). This 
results in a decondensed chromatin confirmation that can be actively transcribed. On the 
other hand, histone deacetylases (HDACs) restore the condensed state, resulting in gene 
silencing by preventing binding of transcription factors and RNA polymerases.40 In the case 
of tumor suppressor genes, this means that tumor development is facilitated. Thus, HDAC 
inhibition could be used to treat cancer. Indeed, Vorinostat (SAHA). a synthetic HDAC in-
hibitor (HDACi) was approved by the FDA in 2006 for the treatment of cutaneous T-cell 
lymphoma.41 Two more (romidepsin (Istodax) and belinostat (Beleodaq)) have followed in 
the past few years and many HDACis are in different stages of clinical trials for various 
hematological and solid tumors.42 Apart from the direct effect of HDCAis on acetylation re-
sulting in re-expression of the gene, HDCAis can also target processes involved in tumor 
progression, cell cycle control, apoptosis, angiogenesis and cell invasion.42 Interestingly, 
HDACis have been shown to suppress SHH activity through Gli1, Gli2 and Gli3 in vitro.43 
A newly designed chimeric compound, NL-103, which integrates the functional inhibitory 
group of the HDACi vorinostat and SHH inhibitor vismodegib, downregulates the expres-
sion of Gli2 in a NIH3T3-12Gli mouse embryo fibroblast cell line. It was concluded that NL-
103 can effectively inhibit SHH and that dual inhibition of HDACs and SHH signaling could 
help to overcome vismodegib44, a phenomenon that is described in more detail in part two.
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The dynamic process of chromatin remodeling is not only regulated by histone acetylation/
deacetylation, but also through ATP-dependent protein complex formation, histone modifi-
cation by polycomb proteins, and by interaction with ncRNAs.40 ncRNAs are RNA fragments 
that are not translated into proteins of which several subtypes can be identified such as miR-
NA, siRNA, piRNA, XiRNA and long ncRNAs.40 RNA interference (RNAi) is a part of a small 
regulatory RNA, including siRNA and miRNA, that regulates gene silencing. RNAi based 
therapies are already being tested in phase 1 studies as treatment in several solid tumors 
(brain, breast) and considered to be safe in use. These drugs have the benefit of being high-
ly specific and they have only little side effects.45 A comprehensive description of all possible 
epigenetic modification processes is beyond the scope of this thesis. But it is evident that 
the rise in knowledge on epigenetic modifications in human cancers like BCC can yield 
considerable diagnostic, therapeutic and even predictive opportunities in the (near) future.
mTOR signaling in BCC
Whereas most research on BCC has been focused on SHH and WNT signaling, it is impor-
tant to think out of the box in order to unravel the pathogenesis of this tumor completely. 
As an example of such thinking, when looking for therapeutic targets we considered that 
BCCs are thought to be hair follicle tumors.46 The hair follicle is considered as a moderately to 
severely hypoxic microenvironment, while the dermis is well oxygenated and the epidermis is 
only modestly hypoxic.47 Therefore we hypothesized that hypoxia response pathways could 
be involved in the pathogenesis of hair follicle tumors such as BCCs. Hypoxia-inducible tran-
scription factor 1 (HIF1) is a primary mediator of hypoxia-induced gene expression in human 
hair follicles.48 HIF1 transcription can be regulated by mechanistic/mammalian target of rapa-
mycin 1 (mTORC1) via 4E-binding protein 1 (4E-BP1), ribosomal protein S6 kinase-1 (S6K1) 
and signal transducer and activation of transcription 3 (STAT3).49 mTORC1 in turn is stimu-
lated by PI3K-Akt signaling pathways and once activated, it promotes several processes like 
angiogenesis, cell growth and tumorigenesis.50 The importance of mTORC1 in the pathogen-
esis of different cancer types, including renal carcinoma and colon carcinoma is well recog-
nized and has already resulted in the development of treatments that target mTORC-depend-
ent signaling events.51 Interestingly, activated mTORC signaling is also associated with the 
development of benign skin tumors like angiofibromas in patients with tuberous sclerosis.48
 
If HIF and mTORC1 pathways do contribute to the growth of hair follicle tumors, new op-
portunities for targeted therapy and diagnostics could emerge. In chapter 3.1 we provide 
a systematic analysis of HIF and mTORC1 signaling in BCC and its benign counterpart, 
trichoepithelioma (TE). TEs strongly resemble BCC both on the macroscopic and micro-
scopic level, but do not exhibit invasive growth. Differentiation between these two hair folli-
cle-derived tumors is important because of their distinct biologic behavior and therapeutic 
approach. Immunohistochemical analysis of HIF1, mTORC1 and their most important target 
genes showed that both HIF and mTORC1 signaling seem to be active in BCC as well as in 
TE. However, there were no appreciable differences between these two tumors with respect 
to pathway activity. To date, immunohistochemical analyses of HIF, mTORC1 and their tar-
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get genes does not provide a reliable diagnostic tool for the discrimination of BCC and TE.
In conclusion, we and others have shown that sporadic BCCs are tumors driven by a variety of 
derailed signaling systems, beyond SHH signaling. This observation is in line with the fact that 
sporadic BCC exhibit a mostly moderate response to targeted SHH inhibitors. There are thus 
several potential drug targets already, and doubtlessly many more remain to be discovered.
Part two: new topical and systemic treatment modalities for BCC
Vitamin D and NSAIDs as anticancer agents
Targeted non-invasive treatments: vitamin D
The primary aim of BCC treatment is complete tumor eradication. However, maximal pres-
ervation of function and cosmesis at the treatment site are very important aspects that must 
be considered when choosing an appropriate therapy. The treatment of choice largely de-
pends on clinical and histopathological characteristics. The risk of recurrence should be 
carefully evaluated in order to avoid overtreatment of low-risk BCCs or under-treatment 
of high-risk BCCs.52 Conventional surgical excision is the gold standard in treatment of 
all BCCs, with success rates varying from 90-98% for primary (untreated) BCCs.53,54 For 
sBCCs, non-invasive treatment modalities such as photodynamic therapy (PDT) (photo-
chemical), imiquimod (immune-modulating) and 5-fluorouracil (5-FU) cream (chemothera-
peutic) are well studied and frequently prescribed.55 Long term tumor-free survival rates 
in sBCCs are high, varying from 72.8-84.0% in PDT, 83.4-87.3% for Imiquimod and tu-
mor-free survival rates of 80.1% were found after treatment with 5-flourouracil.55,56 This il-
lustrates that cure rates following surgical excision are still much higher. At the time of the 
clinical trial described in chapter 4.1, there were no pertinent data to support non-inva-
sive treatments for nBCCs. Likewise, according to the Dutch ‘evidenced-based guideline 
treatment of the basal cell carcinoma’, non-invasive treatment modalities were reserved 
for sBCCs only. We concluded that there was still an opportunity for (the development of) 
alternative or additional non-invasive treatment modalities for sBCCs as well as nBCCs. 
Current research in oncology is focusing on the development of targeted cancer treatments 
that are specifically aimed at key signaling pathways instead of the more generally used, non-
specific cytotoxic agents. Interestingly, sometimes drugs already available for the treatment 
of one disease turn out to be effective against a different disease (including human cancers), 
which is known as drug repurposing. The active metabolite of vitamin D, 1α,25(OH)2D3 
(calcitriol) is of particular interest in this regard. Preclinical research has indicated that this 
metabolite or other vitamin D analogues might have potential as anticancer agents because 
of their antiproliferative effects, activation of apoptotic pathways and inhibition of angiogen-
esis.57 Vitamin D is known to be a steroid hormone crucial in calcium homeostasis and reg-
ulation of bone metabolism. It also has many other biological actions that are still not fully 
characterized.58 In the skin, calcitriol is mainly synthesized under influence of UVB exposure. 
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For that reason, sun protection advice given by dermatologists in order to prevent skin aging 
and skin cancer is often disobeyed because patients fear becoming vitamin D deficient. 
Indeed, sunscreens do block the vitamin D production, however in daily practice, typically 
only little amounts of sunscreen are applied to the skin and vitamin D deficiency therefore is 
not normally an issue. Mean daily exposure during 15-30 minutes (depending on latitude and 
season) of the face, hands and underarms without any sun protection would generate the re-
quired amount of vitamin D in people with Fitzpatrick skin type I-III. However, dermatologists 
and cancer groups, including the Skin Cancer Foundation of the United States discourage 
such unprotected UV exposure, as all unprotected UV exposure contributes to cumulative 
DNA damage and thus to a further increased risk of skin cancer development. Their advice is 
to substitute vitamin D orally. In a time where vitamin D (deficiency) seems to be a real hype, it 
is important to realize that neither the influence of vitamin D insufficiency nor the health benefit 
of maintaining high serum vitamin D levels has been established for the general population.59 
Animal and cellular studies strongly suggest a role for vitamin D in the prevention and treat-
ment of various human cancers. So far, however, clinical studies in most cancers have not yet 
delivered compelling evidence to support the use of vitamin D supplements in daily practice.60
 
In keratinocytes, the vitamin D receptor (VDR) interferes in both SHH- and WNT signaling and 
that way seems to be crucial in the tumorigenic response.61 Also, normal keratinocytes and 
melanocytes respond to calcitriol with a reduction in proliferation and an increase in differen-
tiation.62 There is some evidence to suggest that high vitamin D serum levels might protect 
against BCC development.63 Conversely, an association with higher serum vitamin D levels 
and a higher risk of BCC has also been shown in two studies.64,65 This higher risk may well be 
explained by the fact that whereas UVB exposure does lead to higher vitamin D serum levels, 
it will also cause the DNA damage that results in skin cancer.61 Additionally, previous in vitro 
studies found that high doses of calcitriol can inhibit keratinocyte proliferation, while lower dos-
es may stimulate proliferation.62,66 Apparently, the balance between the positive and negative 
effects of vitamin D is a very delicate one. In our study, described in chapter 4.1, topical calci-
triol applied twice daily to sBCCs and nBCCs during 8 weeks did not have any effect. No histo-
pathological tumor clearance was found, nor was there any effect on the proliferation marker 
Ki-67 and anti-apoptosis marker Bcl-2. However, based on our results we cannot completely 
rule out that vitamin D analogs could treat BCC. The lack of response we observed might have 
been due to calcitriol being unable to reach sufficiently high concentrations in the tumors. 
Targeted non-invasive treatments: diclofenac
Nonsteroidal anti-inflammatory drugs (NSAIDs) are well-known and frequently used drugs 
with analgesic, antipyretic and anti-inflammatory effects. There are many different types of 
NSAIDs. The main class effect is the inhibition of cyclooxygenases 1 (COX-1) and 2 (COX-
2), with a consequent decrease in prostaglandin synthesis. COX-1 is a housekeeping gene 
that is constitutively expressed and controls normal physiological functions such as main-
tenance of the gastric mucosa and platelet function, vascular homeostasis, as well as renal 
blood flow. In contrast, COX-2 is an immediate-early gene, and expression is generally be-
190 | Chapter 6
low detection levels.67 COX-2 modulates cell proliferation, angiogenesis and suppression of 
apoptosis.68 In BCCs, COX-2 is commonly highly expressed under influence of UV radiation 
and multiple other inflammatory stimuli, whereas in normal skin COX-2 is usually undetect-
able.67,68 Diclofenac is the most widely prescribed non-selective COX inhibitor worldwide.69 
Over the past three decades, epidemiologic, clinical, and experimental studies have es-
tablished a chemopreventive effect of NSAIDs in various tissues. However NSAIDs are not 
used as chemopreventive agent because of incomplete efficacy and toxicities.70 The effect 
of the oral selective COX-2 inhibitor Celecoxib on the development of BCCs was studied in 
a double-blinded, randomized controlled clinical trial in 60 patients with BCNS. After Ce-
lecoxib (200 mg, twice daily, 24 months) a trend towards reduction in BCC burden in the 
treatment group in all subjects was sugested.71 A recent meta-analysis did not find a statis-
tically significant chemopreventive effect of NSAIDs on NMSC, not even after stratification 
for the different NSAIDs and for BCCs and SCCs.72 Thus, there is no convincing evidence to 
date that regular use of systemic NSAIDs could serve as chemopreventive agent in the de-
velopment of BCCs. However, as the local bioavailability is expected to be higher after local 
application, and considering the fact that NSAIDs can target the WNT signaling pathway that 
is activated in BCCs73, we assumed that topically applied diclofenac could be effective in 
the treatment of (low-risk) BCCs. Moreover, diclofenac both directly and indirectly induces 
apoptosis.74,75 In chapter 4.1 we showed that application of diclofenac 3% gel with 2.5% 
hyaluronic acid for 8 weeks twice daily (under occlusion) to sBCC resulted in a complete 
histologic regression in 64.3% of all tumors. These results further support inflammation as 
a possible driver of BCC growth (see also part one). The histological clearance found was 
not as high as can be obtained with currently available non-invasive treatment modalities, 
however it should be noted that we made use of a diclofenac compound (Solaraze®) that is 
already FDA approved for the treatment of actinic keratosis (AK).76 Previous dose-response 
studies for its specific use in BCC were not performed. Optimized dosage regimens might 
further improve efficacy. Apart from more targeted mode of action, further advantages of 
topical diclofenac are that it is cost-efficient, easy in use and that it has limited side ef-
fects. This makes topical diclofenac a promising drug for the treatment of (low-risk) BCCs.
Topical diclofenac as chemopreventative agent
Because of the promising results of topical diclofenac as treatment of sBCC and the ever 
larger number of patients affected, it is of interest to determine whether topical diclofenac 
could serve as a chemopreventative agent. About one third of the patients diagnosed with 
their first primary BCC will develop at least one subsequent BCC. This risk is highest within 
the first 6 months after diagnosis, but remains substantially high even after a follow-up period 
of 5 years. In particular patients with red hair, a higher socioeconomic status, and/or those 
with a BCC on their upper extremities have a higher risk of developing multiple BCCs.77
Topically applied 3% diclofenac gel with 2.5% hyaluronic acid (the same formula used in the 
clinical trial in chapter 4.1) has already been used in the treatment of AK and resulted in com-
plete clinical clearance of 41-60% of AKs after 3 months of treatment.76 Topical diclofenac in 
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twice-daily doses is approved by the FDA for the treatment of AK over a period of 60-90 days 
and it is prescribed for this purpose in many European countries, although its use is not rec-
ommended by the ‘Dutch guideline actinic keratosis’. Given the inhibitory effect of diclofenac 
on cell proliferation and the promising response rates both in AK and BCC, topical diclofenac 
could presumably help to reduce the risk of new or subsequent BCC development. The side 
effects are usually mild to moderate (e.g. erythema, pruritus and erosion) and resolve without 
sequelae (chapter 4.1). Therefore, it might be of interest to explore whether diclofenac could 
be used as a preventive additive to daily skin care creams. With a lower concentration or a re-
duced frequency of application, known side effects could be reduced whilst retaining efficacy. 
Targeted non-invasive treatments and future perspectives of BCC management
In contrast to most cancers, skin tumors are readily accessible for clinical examination and 
tissue samples for (immuno)histochemical (IHC) evaluation can easily be obtained. It might 
be argued that accurate clinical follow-up instead histological examination could be consid-
ered when assessing new topical treatments in clinical trials. However, immunohistochem-
ical stains on pre- and post-treatment tissue samples can provide insight in the mode of 
action or efficacy of new treatment modalities. In quantifying the expression levels of specific 
immunohistochemical markers, percentages of positive tumor cells need to be determined. 
Manual pathologist-based quantification (MQ) is still the most frequently used technique for 
IHC evaluation78 and is considered as the gold standard. However, MQ is time-consuming 
and labor-intensive.79 It is also a subjective approach that may have high intra- and inter-ob-
server variability.80-82 Larger studies with more immunohistochemical stains to be investigat-
ed inevitably generate a large number of slides to be assessed, rendering MQ impractical.
Automated, digital image analysis might offer a solution and has been used since the 1980s. 
Several different methods are available.83 We used a so-called operator-dependent semi-au-
tomated quantification (SAQ) computerized thresholding technique (Leica Qwin version 3.5.1, 
Leica Microsystems, Cambridge, UK), which is an extensively evaluated method, especially 
for mammographic density.84,85 SAQ is time saving, provides easily accessible data and gen-
erates good reproducible results, even by generally inexperienced young researchers (chap-
ter 4.2). However, we found large discrepancies between MQ and SAQ, that point to the need 
for studies in which consensus evaluation by more than one pathologist is compared with SAQ 
measurements. Evidence from a well-designed study that SAQ is a reproducible and accurate 
method for assessing immunohistochemical stains would be very relevant for research. Stud-
ies assessing changes in expression values in pre- versus post-treatment tissue samples are 
especially suitable for SAQ, as the change in expression is less susceptible for random errors. 
In chapter 4.1, two pathologists manually assessed all pre- and post-treatment tissue sam-
ples. In contrast to the more promising results in sBCCs, in nBCCs we did not detect sig-
nificant changes in proliferation, apoptosis or total tumor clearance after treatment with di-
clofenac, calcitriol or a combination of both. The difference in response between nBCCs and 
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sBCCs is in agreement with reports from other studies investigating non-invasive therapies. 
sBCCs spread from the epidermis into the papillary dermis, which makes the tumors more ac-
cessible to topical treatment. In contrast, nBCCs show deep, compact, and nodular growth86 
presumably leading to insufficient penetration of topically applied drugs. Only recently, high 
3-year success rates (81.8%) were found for nBCCs treated with imiquimod for 12 weeks, 7 
days a week.54 This is an intensified treatment schedule compared to the presently licensed 
schedule of 5 days a week for 6 weeks. Imiquimod has several antitumor activities. The ma-
jor biological effect of imiquimod is the activation of nuclear factor-kappa B (NF-κB) through 
toll-like receptors 7 (TLR7) and 8 (TLR8). Induction of NF-κB results in the production and 
secretion of pro-inflammatory cytokines and chemokines, stimulating a strong Th1-mediated 
antitumoral cellular immune response.87 Additionally, imiquimod directly stimulates antitu-
moral activation of dendritic cells (DCs). DCs are important (tumor) antigen presenting cells 
in the skin and they are thought to be crucial in generating an aggressive immune response 
against cutaneous cancers.51 Interestingly, a recent study in a Patched1 deficient murine 
BCC cell line suggests that imiquimod may actually serve as a targeted therapy by directly 
inhibiting SHH signaling downstream of SMO. Imiquimod can cause GLI phosphorylation 
and subsequent reduction in GLI target genes.88 The fact that imiquimod, apart from its 
immunomodulating effect, also seems to directly inhibit SHH signaling, could explain why it 
is the most effective topical treatment currently available.55 Indeed (pre-) clinical evidence 
has suggested that simultaneously targeting SHH and other signaling pathways may have 
a synergistic effect.89 In chapter 4.1 we hypothesized that combining diclofenac gel and 
calcitriol ointment would enhance their individual efficacy. In our clinical trial, the combina-
tion did not show the expected synergistic effect. The observed clinical effect of the “com-
bination therapy” arm was probably attributable to diclofenac, as there was no effect at all 
in the calcitriol arm. Since calcitriol ointment was applied five minutes after application of 
diclofenac gel, dilution or suboptimal absorption could explain the observed reduced effi-
cacy compared to diclofenac monotherapy in sBCCs. Of note, in the combination therapy 
group, there were four non-responding tumors that appeared to have a nodular BCC com-
ponent although they were initially diagnosed as sBCC on the biopsy. Since we also found 
that nodular BCCs did not respond to topical therapy, treatment failure in these patients was 
probably related to the histological subtype. Due to the sample size of 16 tumors per arm, 
those 4 non-responders with a different histological subtype had a large impact on the over-
all treatment outcome. Nevertheless, the promising results of topical diclofenac in sBCCs 
suggest new possibilities for the management of BCCs. Further optimization with dose-re-
sponse trials and studies combining topical diclofenac with available (targeted) non-invasive 
therapies are needed to test whether topicals can obtain cure rates comparable to those of 
the gold standard, surgery. Based on our present understanding, treatment with diclofenac 
gel and imiquimod cream is a promising combination that we are currently investigating.
Non-invasive treatments in general can be expected to have several advantages, making 
them worth pursuing. They will generally give a better cosmetic outcome, with an increased 
quality of life for patients as a result.54 Patients will be able to treat themselves at home, 
which makes them less dependent on hospital care. A second advantage of this home-
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based treatment is that the workload for dermatologists will decrease, resulting in lower 
overall healthcare costs. Since the skin cancer epidemic is yet to peak, the workload for 
dermatologists is expected to increase. General practitioners might be able to help in this 
increase in demand. However, according to a self-administered questionnaire filled in by 
268 general practitioners, over 50% of the general practitioners felt the need to know more 
about skin cancer care.90 Intensified training programs on recognition and management of 
skin cancer are therefore essential to facilitate treatment by non-specialists. General practi-
tioners are already used to take biopsies of suspicious lesions, but they generally do not per-
form therapeutic surgical excisions of BCCs (yet). Also, in general, they are not familiar with 
prescribing non-invasive treatments. Good collaborations between the general practitioners 
and dermatologists are necessary to improve care of the patient with (pre-) skin cancer, and 
is essential in order to reduce health care costs. The department of dermatology (MUMC) 
already collaborates with general practitioners in the so called ‘1.5th line of care’ or ‘stad-
spoliklinieken’, where dermatologists visit the general practitioner one day a week in order 
to facilitate dermato(onco-)logical care by reducing the number of unnecessary referrals to 
the hospital. Another way to make current dermatological practice more efficient is the em-
ployment of specialized nurse practitioners and physician assistants, who could participate 
in the management of skin cancer. Of course, oncological care of the skin should then be 
thoroughly implemented in their educational training. With the appropriate knowledge, these 
paramedics could not only educate patients about skin cancer prevention, but they would 
also be able to recognize (pre-) skin malignancies and potentially even treat AK and low-risk 
BCCs.91 Of note, high risk BCC, SCC and malignant melanoma should always be treated by 
a dermatologist, as they are associated with higher morbidity and even mortality. However, 
paramedics could serve as a first point of call for BCC patients and help manage further 
care. It should be stressed that paramedics should always collaborate with a dermatologist. 
Targeted SMO-inhibitors in BCC
Vismodegib and (acquired) resistance
BCC is characterized by abberant activation of the SHH pathway, mostly due to inactivating 
mutations in the tumor suppressor gene PTCH1 or activating mutations in the SMO onco-
gene.92 SHH-inhibitors specifically target SMO, but GLI or other downstream pathway com-
ponents may be targeted in the near future.93 Vismodegib (Erivedge™, also known as GDC-
0449) is an orally active synthetic SMO inhibitor and was approved by the FDA in 2012 for the 
treatment of laBCC and mBCC.94 In July 2015, a second SMO inhibitor, sonidegib (Odomzo™, 
also known as LDE255), was approved by the FDA for laBCC not amenable to curative surgery 
or radiation therapy.95 As the mode of action of these Hedgehog Pathway Inhibitors (HPIs) is 
identical, similar efficacy rates and adverse events are seen (class effect).95,96 Recently, pre-
planned interim results of the largest international, open label trial to the safety and efficacy 
of vismodegib in laBCC and mBCC (STEVIE study) were published.97 After at least 12 months 
of treatment, complete and partial response was seen in 32% of laBCC and 33% of mBCC 
patients. Twenty-seven percent of all patients treated had stable disease and progressive 
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disease was seen in 3% of the patients. The mean duration of treatment was 36.3 weeks for 
laBCCs and 52.0 weeks for mBCCs. Treatment was discontinued in no less than 80% of all 
patients treated in this study. Almost all patients reported one or more adverse events (99%), 
of which the most important events where muscle spasms, alopecia and dysguesia (loss of 
taste). These adverse events were the most important reason for treatment discontinuation. 
The authors concluded that the safety profile described in the STEVIE study was consist-
ent with previous analyses of vismodegib in patients with laBCC and mBCC.97 The depart-
ment of dermatology of the MUMC participated in this STEVIE trial and included 6 patients.
Initial response to vismodegib followed by secondary tumor progression has been observed 
and is suggested to occur in 20% of the patients within the first year of treatment.98-102 The 
mechanisms underlying resistance to vismodegib in BCCs may clinically be divided into pri-
mary resistance (no response to treatment) or secondary (acquired) resistance (progression 
after an initial response).103 We purposely speak of a clinical classification, because it is still 
unclear whether the non-responding tumor cells are already present in the primary tumor and 
grow out to visible tumor due to selection, or whether HPIs may even induce mutations that 
lead to resistance. Acquired resistance to vismodegib has also been described in medullo-
blastoma, caused by a heterozygous SMO mutation that appeared in the metastatic medul-
loblastoma during treatment.104 In this thesis, two patients with laBCCs who had developed 
respectively primary and secondary resistance to vismodegib are outlined. Chapter 5.1 de-
scribes two heterozygous mutations ((p.Trp281Leu and p.Val321Met) in newly developed 
tumor tissue after 20 weeks of treatment in a laBCC patient who initially had a good clinical 
response to vismodegib. Neither SMO mutation was found in the laBCC biopsy specimen 
obtained before initiation of vismodegib therapy, or in the biopsy specimens of responding 
sclerotic skin during therapy. Analysis of a buccal swab revealed no mutations at all. It is 
of particular interest that the same novel somatic PTCH1 mutation was detected in both the 
primary and the resistant BCC, and was absent in clinically and histologically responding 
tissue. This observation implies that cells from the original tumor had survived. Thus, even 
though the resistant tumors arose from the same, clonal primary tumor, a clonal origin of the 
resistant BCC nests is precluded, a finding that supports tumor heterogeneity. Interestingly, 
the SMO codon 321 that we found was previously described as a critical binding site for 
vismodegib binding102, but codon 281 has never been related to vismodegib resistance. It 
appears that resistance to vismodegib in BCC can be caused by several different acquired 
SMO mutations that interfere with drug binding, a finding that is also described by Sharpe 
et.al.92 Also, in a few resistant cases, recurrent copy number variants in the downstream 
effectors SUFU and Gli2 were detected. There is a complex interplay between mutual and 
heterogeneous resistance mechanisms to SMO inhibition in BCCs, even within the same 
tumor.92 The fact that sporadic BCC is a very heterogeneous tumor is confirmed by whole-ex-
ome sequencing of the genetic landscape of BCC, showing that BCCs harbor the most mu-
tations of all known human cancers.28 From this point of view, it could be suggested that the 
use of oral SMO inhibitors like vismodegib should be reserved for BCNS patients only, given 
the fact that these BCC are presumed to be obligatory and solely SHH driven, in contrast 
with sporadic BCC that appears to be more multifactorial (see part one of this discussion). 
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A better understanding of the tumorigenesis of sporadic BCC and the mechanisms under-
lying vismodegib resistance is important for the development of alternative treatment strate-
gies. Sequential mutation analysis on pre-treatment and recurrent tumor tissue may help to 
anticipate on the type of resistance (either primary or secondary) in order to actively alter 
therapy. Then, treatment schedules and combination therapies can be customized to both 
patient and tumor characteristics, in an example of so-called personalized medicine. Over-
all, possible therapeutic approaches are sequential or rotational therapy with non-treatment 
periods (‘drug holidays’) in order to obtain a better tolerability for side effects, combination 
therapies, or alternating different therapies. Combining different systemic therapies in laBCC 
or mBCC may have the advantage of synergistic or additional therapeutic effects, lower 
dosage application and, possibly, the prevention of (acquired) resistance.105 In addition, 
systemic itraconazole and nicotinamide might be promising agents in BCC treatment.106,107
Vismodegib, SCC and future analyses 
Chapter 5.2 discusses a patient with a 15-year history of a recurrent infiltrative BCC of the 
nose and right cheek, who was included in the STEVIE study and treated with vismodegib. 
No clinical improvement was observed and we even feared for progression into SCC as 
impressive hyperkeratosis developed after 7 weeks of treatment. Formation of SCC within 
the initial BCC has been reported in several case studies describing patients treated with 
vismodegib, as has development of SCC and keratoacanthoma on other body sites.108-113 In 
our patient, histologic examination of tissue specimens acquired during surgery performed 
5 months after initiation of vismodegib treatment, revealed residual BCC cells with positive 
staining for staining Ber-Ep4 (BCC marker). No signs of basosquamous carcinoma or SCC 
were found. Also, there were epidermal cysts that stained negatively for Ber-Ep4, exclud-
ing the possibility that these were BCC remnants that had survived of the original tumor. A 
possible explanation for the emergence of the benign squamous neoplasms could be the 
effect of vismodegib on keratinocyte differentiation. Vismodegib can mimic the loss of Indian 
hedgehog (IHH), a member of the HH ligand family the loss of which was shown to promote 
the progression of benign papillomas to SCC.114 In the case of SCCs emerging upon SMO 
inhibition, it has been hypothesized that a phenotypic switch from BCC to SCC, caused by 
new mutations (NOTCH1/2 and KMTC2), could occur as a mechanism of tumor escape.115 
Secondly, SMO inhibition might promote carcinogenesis by selecting tumor cells driven by 
other molecular pathways, like RAS/MAPK signaling. Activation of RAS/MAPK signaling can 
override the oncogenic addiction of the tumor to SHH signaling and thereby enabling pro-
liferation of resistant tumors with enhanced metastatic behavior.116 However, further func-
tional analysis is needed if the complex effects of vismodegib on keratinocyte differentiation 
and proliferation. Unfortunately, we were not able to perform any mutational analyses in our 
patient, mostly because no pre-treatment fresh frozen tissue samples had been obtained.
 
In daily dermatological and pathological practice, tissue samples acquired for diagnos-
tic considerations are generally formalin-fixed paraffin-embedded (FFPE). DNA extracted 
from FFPE is fragmented and can also contain sequence artifacts arising from DNA dam-
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age that can be difficult to distinguish from true mutations, especially in highly heteroge-
neous tumors such as BCC. These sequence variants are more often seen in FFPE than in 
fresh frozen tissue.117 One of the potential techniques to overcome this problem is the use 
of molecular inversion probes (MIPs). MIPs provide a practical, highly sensitive method for 
the detection of low-frequency mutations and subclonal variations in FFPE, requiring low 
amount of sample input, while per-sample costs are very low.118 This technique makes it 
possible to retrospectively perform pre- and post-treatment analysis. Such approaches will 
help to further unravel mechanisms of resistance, not only to vismodegib in BCC, but also 
to other small molecule inhibitors used to treat human malignancies such as melanoma.
Vismodegib and its place in daily dermatological practice
Systemic targeted treatments such as vismodegib are associated with potential toxicities 
and the number of patients reporting adverse events is considerably high, making its use 
limited to laBCCs and mBCCs. However an international multicenter clinical trial to the effi-
cacy and safety of two different vismodegib regimens in patients with multiple BCC (MIKIE) 
(NCT01815840, clinicaltrials.gov) is currently ongoing. This study already anticipates on the 
fact that this group of patients will require a long-term treatment by introducing rotational 
therapy in which ‘drug-holidays’ of 8 weeks are implemented in an attempt to minimize ad-
verse events. It can be speculated that also the occurrence of resistance may be diminished 
following rotational therapy. The interim results of the STEVIE study showed a median time 
to first onset of the most common adverse events of 2.83 months for muscle spasms, 5.55 
months for alopecia, and 6.51 months for dysgeusia.96 The side effects are cumulative and 
tend to get worse with increasing duration of the treatment. Temporary treatment stops e.g. 
every 3 months will lower or even prevent the burden of adverse events and is specially 
desirable in patients with multiple BCCs and BCNS. The possibility to use vismodegib in al-
ternating treatment schedules in order to support a longer maintenance on treatment would 
provide an extra indication for FDA approval for this indication. However, experts in the 
field already implement drug-holidays, especially in BCNS patients, in which the treatment 
regimen is personalized to the patient and mainly patient driven rather than doctor driven. 
Interesting is a phase II, single-armed, multicenter trial (the NICCI trial), assessing the utility 
of vismodegib as neo-adjuvant treatment prior to surgery in laBCC and rBCC.119 Although 
currently still off-label, limited case reports already describe results of neo-adjuvant treat-
ment of laBCCs with vismodegib.98,120,121 Neo-adjuvant therapy with vismodegib was effective 
in reducing the surgical defect, leading to less scarring and morbidity. However, long term 
follow-up is lacking and BCC remnants were found during Mohs surgery in the majority of the 
cases after three to six months of treatment with vismodegib.98,120,121 One should be aware of 
the fact that reduction of BCC nests following vismodegib not necessarily occurs from the 
periphery to the center of the tumor. Thus when performing Mohs surgery of only the center 
of the clinically remaining tumor, (subclinical) scattered tumor nests in het former tumor area 
are probably missed. This inevitably results in inadequate treatment and a high risk of re-
currence. If therapy is optimized possibly by combination therapy, and the percentage of 
resistance for therapy is decreased, we do agree that planning patients for surgical excision 
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may reduce the chance of recurrence and could offer interesting further treatment options. 
Currently, the use of vismodegib as systemic treatment is limited to laBCCs and mBCCs 
because of potential toxicities which do not outweigh the disadvantages of available treat-
ments of regular low-risk BCCs. In these low risk tumors, topical SMO inhibitors would 
have a broader applicability, however the results of their effectiveness in humans are 
rather disappointing. Topical CUR61414 had little or no effect on proliferation and apop-
tosis of BCCs, assessed by Ki-67 and cleaved caspase-3 immunohistochemical stains re-
spectively, probably due to low penetration or rapid clearance of the active component.122 
LDE225 0.75% cream is a different topical SMO inhibitor and although clinical regression 
is seen in almost all BCCs of eight BCNS patients after 4 weeks of treatment, histologi-
cal examination of post-treatment biopsy samples of all tumors revealed that tumor nests 
were still present. A major advantage of topical application is the excellent safety profile 
with no local or systemic side effects.123 Topical SMO inhibitors could emerge as an at-
tractive non-invasive alternative for low-risk BCCs. However, future studies are needed 
to improve their efficacy and provide confident evidence for their use in daily practice. 
The development and availability of small-molecule (targeted) inhibitors as vismodegib offer a 
new area in the management of BCC. As the dermatologist is the specialists with the most ex-
perience in treatment of different forms of skin cancer and the only specialist that has accessi-
bility to all available treatment options, the dermatologist should always be involved in setting 
the indication for such treatments. In any case a multidisciplinary team in which the dermatol-
ogist, medical oncologist, plastic surgeon, radiotherapist and ENT-specialist closely cooper-
ate should be involved. As laBCC/mBCC is generally a disease of the elderly, comorbidities 
and polypharmacy are not uncommon. The management of these patients requires a more 
holistic approach. Some have argued that the prescription and treatment with vismodegib 
should be restricted to medical oncologists. However, most dermatologists are experienced 
in prescribing systemic drugs and even cytostatic drugs and they are capable of dealing with 
possible side effects and adverse events. Treatment should be supervised by the physician 
who is experienced in the patient’s ill-health and it is likely that the physician who decides to 
start vismodegib is the main therapist. In mBCCs, this could be the medical oncologist, but in 
laBCCs treatment by the dermatologists seems more logical. A good collaboration between all 
members of the multidisciplinary team is a key point. As the number of patients is limited, it is 
important to gain and share experiences with all team members and discuss cases regularly.
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